A Phase I Randomized Placebo Controlled Trial of the Safety of 3% SPL7013 Gel (VivaGel®) in Healthy Young Women Administered Twice Daily for 14 Days

Overview of attention for article published in PLOS ONE, January 2011

Altmetric Badge

Mentioned by

news: 5 news outlets

twitter: 2 X users

Citations

dimensions_citation: 66 Dimensions

Readers on

mendeley: 65 Mendeley

Summary News X Dimensions citations

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 386 followers.

@CharmsYahoo @MeetJess @ejustin46 VivaGel (astodrimer sodium) used in vagina twice daily for 14 days by young women in USA & Kenya. Adverse effects with only 14 days’ use of 3%. https://t.co/iDaGJDNAWa What will be adverse effects frm using 1% over fe

23 Feb 2023

Reply Repost Favourite

Comment on Cohen CR (2011): A phase I randomized placebo controlled trial of the safety of 3% SPL7013 Gel (VivaG https://t.co/LD9apWSoUp

23 Aug 2016

Reply Repost Favourite

PLOS

Article Metrics

A Phase I Randomized Placebo Controlled Trial of the Safety of 3% SPL7013 Gel (VivaGel®) in Healthy Young Women Administered Twice Daily for 14 Days

Mentioned by

Citations

Readers on